加药
医学
多发性骨髓瘤
抗体
毒性
肿瘤科
内科学
地铁列车时刻表
免疫学
计算机科学
操作系统
作者
Niels W.C.J. van de Donk,Leo Rasche,Surbhi Sidana,Sonja Zweegman,Alfred L. Garfall
出处
期刊:Blood cancer discovery
[American Association for Cancer Research]
日期:2024-09-25
标识
DOI:10.1158/2643-3230.bcd-24-0124
摘要
Abstract T-cell redirecting bispecific antibodies (BsAbs) induce significant responses in heavily pretreated MM. BsAbs are currently administered in a dose-dense fashion until disease progression. However, continuous therapy is associated with safety concerns, including a high risk of infections, and high costs. In addition, chronic exposure to BsAbs, and thus long-term T-cell stimulation, induces T-cell exhaustion, which may contribute to relapse. There is increasing evidence that the strategy of induction treatment followed by maintenance with longer intervals between BsAb doses, or limited treatment duration with cessation of therapy in patients who achieve deep remission, improves the balance between toxicity and efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI